Literature DB >> 2524399

Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion.

G Di Renzo1, S Amoroso, M Taglialatela, L Canzoniero, V Basile, A Fatatis, L Annunziato.   

Abstract

The present study was undertaken to characterize the type of serotonin (5-HT) receptors involved in the control of prolactin (PRL) secretion in male rats. d-Fenfluramine (10 mg/kg i.p.), a potent 5-HT releaser and quipazine, (20 mg/kg i.p.) a 5-HT agonist, caused a marked increase in serum PRL levels. Ritanserin (200 micrograms/kg i.p.), a specific antagonist of 5-HT2 receptors, administered 1 h before the administration of d-fenfluramine or quipazine, completely prevented the PRL-releasing effect of these drugs. Furthermore, the administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) (1.5, 3 and 6 mg/kg i.p.), a compound considered to be a prototypical 5-HT1A agonist, failed to induce any change in serum PRL levels. The same lack of effect on PRL secretion was observed after the administration of 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridin-4-yl)-1-H-indole (RU 24969) (1, 3 and 10 mg/kg i.p.), a compound which has been shown to possess a higher selectivity for 5-HT1B receptor subtypes than for 5-HT1A subtypes. These results suggest that 5-HT receptors involved in the control of PRL secretion are of the 5-HT2 type.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524399     DOI: 10.1016/0014-2999(89)90302-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  The 5-HT receptor--G-protein--effector system complex in depression. I. Effect of glucocorticoids.

Authors:  K P Lesch; B Lerer
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

Authors:  E M Goodall; P J Cowen; M Franklin; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects.

Authors:  Emil F Coccaro; Royce Lee; Richard J Kavoussi
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

5.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

6.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

7.  Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.

Authors:  H Y Meltzer; M Maes
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

8.  Gonadotropin and prolactin secretion in prepubertal female rats treated with 8-hydroxy-2-(di-n-propylamino) tetralin.

Authors:  E Aguilar; A Ranchal; R Aguilar; L Pinilla
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man.

Authors:  E Palazidou; J Stephenson; J Butler; P Coskeran; S Chambers; A M McGregor
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

10.  Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects.

Authors:  R S Kahn; M A Kling; S Wetzler; G M Asnis; H van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.